Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease.

BACKGROUND Increased concentrations of remnant cholesterol are causally associated with increased risk of ischemic heart disease. We tested the hypothesis that increased remnant cholesterol is a risk factor for all-cause mortality in patients with ischemic heart disease. METHODS We included 5414 Danish patients diagnosed with ischemic heart disease. Patients on statins were not excluded. Calculated remnant cholesterol was nonfasting total cholesterol minus LDL and HDL cholesterol. During 35836 person-years of follow-up, 1319 patients died. RESULTS We examined both calculated and directly measured remnant cholesterol; importantly, however, measured remnant cholesterol made up only 9% of calculated remnant cholesterol at nonfasting triglyceride concentrations <1 mmol/L (89 mg/dL) and only 43% at triglycerides >5 mmol/L (443 mg/dL). Multivariable-adjusted hazard ratios for all-cause mortality compared with patients with calculated remnant cholesterol concentrations in the 0 to 60th percentiles were 1.2 (95% CI, 1.1-1.4) for patients in the 61st to 80th percentiles, 1.3 (1.1-1.5) for the 81st to 90th percentiles, 1.5 (1.1-1.8) for the 91st to 95th percentiles, and 1.6 (1.2-2.0) for patients in the 96th to 100th percentiles (trend, P < 0.001). Corresponding values for measured remnant cholesterol were 1.0 (0.8-1.1), 1.2 (1.0-1.4), 1.1 (0.9-1.5), and 1.3 (1.1-1.7) (trend, P = 0.006), and for measured LDL cholesterol 1.0 (0.9-1.1), 1.0 (0.8-1.2), 1.0 (0.8-1.3), and 1.1 (0.8-1.4) (trend, P = 0.88). Cumulative survival was reduced in patients with calculated remnant cholesterol ≥1 mmol/L (39 mg/dL) vs <1 mmol/L [log-rank, P = 9 × 10(-6); hazard ratio 1.3 (1.2-1.5)], but not in patients with measured LDL cholesterol ≥3 mmol/L (116 mg/dL) vs <3 mmol/L [P = 0.76; hazard ratio 1.0 (0.9-1.1)]. CONCLUSIONS Increased concentrations of both calculated and measured remnant cholesterol were associated with increased all-cause mortality in patients with ischemic heart disease, which was not the case for increased concentrations of measured LDL cholesterol. This suggests that increased concentrations of remnant cholesterol explain part of the residual risk of all-cause mortality in patients with ischemic heart disease.

[1]  D. Demicco,et al.  Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. , 2015, Journal of the American College of Cardiology.

[2]  B. Nordestgaard,et al.  Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. , 2015, Clinical chemistry.

[3]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[4]  J. Borén,et al.  Review the Polygenic Nature of Hypertriglyceridaemia: Implications for Defi Nition, Diagnosis, and Management , 2022 .

[5]  B. Nordestgaard,et al.  Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. , 2014, Clinical chemistry.

[6]  E. Boerwinkle,et al.  Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[7]  B. Nordestgaard,et al.  Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. , 2014, Pharmacology & therapeutics.

[8]  B. Nordestgaard,et al.  Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. , 2014, Journal of clinical lipidology.

[9]  G. Watts,et al.  Demystifying the management of hypertriglyceridaemia , 2013, Nature Reviews Cardiology.

[10]  Tanya M. Teslovich,et al.  Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.

[11]  B. Nordestgaard,et al.  Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.

[12]  G. Corrao,et al.  Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. , 2013, Atherosclerosis Supplements.

[13]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[14]  D. Waters,et al.  Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study , 2012, Circulation.

[15]  U. Sampson,et al.  Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges , 2012, Current Atherosclerosis Reports.

[16]  P. Schnohr,et al.  Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow‐up , 2011, Journal of internal medicine.

[17]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[18]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[19]  Anne Tybjærg-Hansen,et al.  Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. , 2011, Journal of the National Cancer Institute.

[20]  Eric Boerwinkle,et al.  The Atherosclerosis Risk in Communities (ARIC) Study , 2011 .

[21]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[22]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[23]  K. Pfeiffer,et al.  Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Christopher P Cannon,et al.  Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. , 2008, Journal of the American College of Cardiology.

[25]  J. Borén,et al.  Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .

[26]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[27]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[28]  S. Proctor,et al.  Arterial retention of apolipoprotein B48- and B100-containing lipoproteins in atherogenesis , 2002, Current opinion in lipidology.

[29]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[30]  R. Wootton,et al.  Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[31]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[32]  B. Nordestgaard,et al.  Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[33]  R. Wootton,et al.  Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[34]  D. B. Zilversmit Atherogenesis: a postprandial phenomenon. , 1979, Circulation.